Lactams as EP4 prostanoid receptor agonists. 3. Discovery of N-ethylbenzoic acid 2-pyrrolidinones as subtype selective agents

Journal of Medicinal Chemistry

Volumn 47, Issue 25, 2004, Pages 6124-6127

  Elworthy, Todd R ^a   Brill, Emma R ^a   Chiou, San San ^a,b   Chu, Frances ^a   Harris, Jason R ^a,c   Hendricks, R Than ^a   Huang, Jane ^a   Kim, Woongki ^a   Lach, Leang K ^a,d   Mirzadegan, Tara ^a   Yee, Calvin ^a   Walker, Keith A M ^a  

^a ROCHE BIOSCIENCE   (United States)

^b ELAN PHARMACEUTICALS   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d ARYx Therapeutics   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZOIC ACID DERIVATIVE; LACTAM DERIVATIVE; POLYCYCLIC AROMATIC HYDROCARBON DERIVATIVE; PROSTAGLANDIN E RECEPTOR; PROSTAGLANDIN E4 RECEPTOR; PROSTAGLANDIN E4 RECEPTOR AGONIST; PROSTAGLANDIN RECEPTOR; PROSTAGLANDIN RECEPTOR AFFECTING AGENT; PROSTANOID; PYRROLIDINE DERIVATIVE; RECEPTOR SUBTYPE; UNCLASSIFIED DRUG; EP4 RECEPTOR; LACTAM; PLASMA PROTEIN; PROSTAGLANDIN EP2 RECEPTOR;

ARTICLE; BINDING AFFINITY; DISTRIBUTION VOLUME; DRUG CONFORMATION; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; DRUG SYNTHESIS; NONHUMAN; PHARMACOPHORE; RAT; STRUCTURE ACTIVITY RELATION; ANIMAL; CHEMICAL STRUCTURE; CONFORMATION; DRUG POTENTIATION; HALF LIFE TIME; HUMAN; METABOLISM; MONTE CARLO METHOD; OXIDATION REDUCTION REACTION; PROTEIN BINDING; SYNTHESIS;

ANIMALS; BENZOIC ACIDS; BLOOD PROTEINS; HALF-LIFE; HUMANS; LACTAMS; MODELS, MOLECULAR; MOLECULAR CONFORMATION; MONTE CARLO METHOD; OXIDATION-REDUCTION; PROTEIN BINDING; PYRROLIDINES; RATS; RECEPTORS, PROSTAGLANDIN E; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 9744245978     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm049290a     Document Type: Article

References (18)

1. Rodan, G. A.; Martin, T. J. Therapeutic Approaches to Bone Diseases. Science 2000, 289, 1508-1514.
2. Reeve, J. PTH: A Future Role in the Management of Osteoporosis? J. Bone Miner. Res. 1996, 11, 440-445.
3. Vickery, B. H.; Avnur, Z.; Cheng, Y.; Chiou, S.-S.; Leaffer, D.; Caulfield, J. P.; Kimmel, D. B.; Ho, T.; Krstenansky, J. L. RS-66271, a C-Terminally Substituted Analog of Human Parathyroid Hormone Related Protein (1-34), Increases Trabecular and Cortical Bone in Ovariectomized, Osteopenic Rats. J. Bone Miner. Res. 1996, 11, 1943-1951.
4. Body, J.-J.; Gaich, G. A.; Scheele, W. H.; Kulkarni, P. M.; Miller, P. D.; Peretz, A.; Dore, R. K.; Correa-Rotter, R.; Papaioannou, A.; Gumming, D. C.; Hodsman, A. B. A Randomized Double-Blind Trial To Compare the Efficacy of Teriparatide [Recombinant Human Parathyroid Hormone (1-34)] with Alendronate in Postmenopausal Women with Osteoporosis. J. Clin. Endocrinol. Metab. 2002, 87, 4528-4535.
5. 2 Increases Bone Strength in Intact Rats and in Ovariectomized Rats with Established Osteopenia. Bone 1998, 23, 249-255.
6. (a) Cattral, M. S.; Altraif, I.; Greig, P. D.; Blendis, L.; Levy, G. A. Toxic Effects of Intravenous and Oral Prostaglandin E Therapy in Patients with Liver Disease. Am. J. Med. 1994, 97, 369-373.
7. (b) Sonmez, A. S.; Birincioglu, M.; Kaya Ozer, M.; Kutlu, R.; Chuong, C. J. Effects of Misoprostol on Bone Loss in Ovariectomized Rats. Prostagl. Lipid Mediators 1999, 57, 113-118.
8. Collins, P. W. Misoprostol: Discovery, Development, and Clinical Applications. Med. Res. Rev. 1990, 10, 149-172.
9. Suda, M.; Tanaka, K.; Natsui, K.; Ushi, T.; Tanaka, I.; Fukushima, M.; Shigeno, C.; Konishi, J.; Narumiya, S.; Ichikawa, A.; Nakao, K. Prostaglandin E Receptor Subtypes in Mouse Osteoblastic Cell Line. Endocrinology 1996, 737, 1698-1705.
10. 4 Prostanoid Receptor Subtype Agonists. Part 1, 2-Pyrrolidinones-Stereochemical and Lower Side-Chain Optimization. Bioorg. Med. Chem. Lett. 2004, 14, 1655-1659.
11. 4 Prostanoid Receptor Subtype Selective Agonists. Part 2. Preparation and Characterization of Longer-Acting Agonists. Presented at the 29th National Medicinal Chemistry Symposium of the American Chemical Society, Madison, Wisconsin, June 27 through July 1, 2004; Abstract 72.
12. 1 and Related Compounds. Chem. Pharm. Bull. 1980, 28, 1449-1458.
13. Jones, J. H.; Holtz, W. J.; Bicking, J. B.; Cragoe, E. J., Jr.; Mandel, L. R.; Kuehl, F. A., Jr. 11,12-Secoprostanoids. 4. 7-(N-Alkylmethanesulfonamido) heptanoic acids. J. Med. Chem. 1977, 20, 1299-1304.
14. 1 analogues on guinea pig and human respiratory tract. Prostaglandins 1979, 18, 787-791.
15. 2-Receptor Agonist. Bioorg. Med. Chem. Lett. 2001, 11, 2025-2029.
16. Fujita, M.; Kitagawa, O.; Yamada, Y.; Izawa, H.; Hasegawa, H.; Taguchi, T. Synthesis of Optically Active 5-Substituted-2-pyrrolidinone Derivatives Having Atropisomeric Structure and 3,5-Cis-Selective Reaction of Their Enolates with Electrophiles. J. Org. Chem. 2000, 65, 1108-1114.
17. 3P in aqueous THF.
18. 1 Derivatives with High Selectivity. Bioorg. Med. Chem. 2002, 10, 989-1008.